Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 15/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258454 | 0.86 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL7258956 | 0.85 | AGPAT2 (0.79) | AGPAT2SENP7CASP3SENP8SENP6 | |
| SCHEMBL7259218 | 0.84 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL7262550 | 0.83 | AGPAT2 (0.82) | AGPAT2SENP7CASP3SENP8SENP6 | |
| SCHEMBL7258728 | 0.81 | AGPAT2 (1.00) | AGPAT2SENP7CASP3SENP8SENP6 | |
| SCHEMBL7258910 | 0.77 | AGPAT2 (1.00) | AGPAT2SENP7CASP3SENP8SENP6 | |
| SCHEMBL7258449 | 0.75 | AGPAT2 (1.00) | AGPAT2 | |
| SCHEMBL7258477 | 0.75 | AGPAT2 (0.60) | AGPAT2PKMSENP7CASP3SENP8 | |
| SCHEMBL7551712 | 0.73 | EPHX2 (0.64) | AGPAT2SENP7CASP3SENP8SENP6 | |
| SCHEMBL11014197 | 0.73 | AGPAT2 (0.57) | AGPAT2PKMSENP7CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | claimed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| WO-2002036580-A9 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002036580-A2 | BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107269-A1 | Benzoxazole LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | AGPAT2 49/4885PKM 1668/4885SENP7 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.